Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.52 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymoctonan SCHEMBL15532000 | 0.93 | REN (0.52) | OPRD1OPRK1F2RENNTSR2 | |
| Thymoctonan SCHEMBL1230532 | 0.93 | REN (0.52) | OPRD1OPRK1F2RENNTSR2 | |
| SCHEMBL30259604 | 0.93 | REN (0.53) | OPRD1OPRK1F2RENNTSR2 | |
| SCHEMBL30011888 | 0.91 | OPRM1 (0.55) | OPRK1REN | |
| SCHEMBL20769314 | 0.88 | ACE (0.58) | OPRK1F2RENNTSR2NTSR1 | |
| SCHEMBL20769315 | 0.88 | ACE (0.58) | OPRK1F2RENNTSR2NTSR1 | |
| SCHEMBL20769313 | 0.88 | ACE (0.58) | OPRK1F2RENNTSR2NTSR1 | |
| SCHEMBL29666135 | 0.87 | OPRK1 (0.58) | OPRD1OPRK1REN | |
| SCHEMBL17456231 | 0.86 | REN (0.51) | OPRD1OPRK1RENACE | |
| SCHEMBL31323239 | 0.86 | CALCRL (0.56) | OPRD1F2PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4129318-A1 | PROTEIN-BASED PHARMACEUTICAL COMPOSITION WITH NEUROPROTECTIVE, IMMUNOMODULATING, ANTI-INFLAMMATORY AND ANTIMICROBIAL ACTIVITY | Centro Nacional de Biopreparados (CU) | 2023-02-08 | — | — | EP | disclosed |
| CN-115209908-A | Protein-based pharmaceutical compositions with neuroprotective, immunomodulatory, anti-inflammatory and antimicrobial activities | 国家生物医学中心 | 2022-10-18 | — | — | CN | disclosed |
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | OPRD1 3100/4885OPRK1 2737/4885F2 2099/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | OPRD1 3859/4885OPRK1 3229/4885F2 3457/4885 |
| US-20110171312-A1 | MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE | DNPEP, VIP, PTMS | OPRD1 2871/4885OPRK1 2169/4885F2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.